## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.0% below STRENGTH zone (4.0-10.0%); PEG 3.69 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($93.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Bearish Options Activity Emerges on Medtronic plc (MDT) Despite Long-Term Growth Outlook**
- Source: Insider Monkey | 20251230T180837 | Neutral | Relevance: 100%
- Medtronic (MDT) is experiencing bearish options activity, with significant put volume reported despite positive regulatory news and long-term growth prospects. This comes after Truist Securities lowered its price objective on MDT due to macro headwinds. The company recently filed to spin off its Diabetes business as MiniMed, aiming to focus on higher-growth segments.

**2. 73,839 Shares in Medtronic PLC $MDT Bought by Oak Harvest Investment Services**
- Source: MarketBeat | 20251230T122035 | Bullish | Relevance: 100%
- Oak Harvest Investment Services recently acquired 73,839 shares of Medtronic PLC (MDT) valued at approximately $7.03 million in Q3. Medtronic reported strong Q results, exceeding EPS and revenue estimates, and provided positive FY2026 guidance. The company also declared a quarterly dividend of $0.71, and boasts a "Moderate Buy" consensus rating from analysts, with institutional investors holding a significant portion of its shares.

**3. Bioelectric Medicine Market is Thriving Worldwide | Medtronic**
- Source: openPR.com | 20251230T120835 | Bullish | Relevance: 100%
- The global bioelectric medicine market, valued at USD 23.27 billion in 2025, is projected to reach USD 43.09 billion by 2032, exhibiting a CAGR of 9.2%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report provides a comprehensive analysis of market drivers, restraints, opportunities, and competitive landscapes, featuring key companies like Medtronic plc. and Boston Scientific Corporation.

**4. Diversified Trust Co Acquires 23,906 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251230T101434 | Bullish | Relevance: 100%
- Diversified Trust Co increased its stake in Medtronic PLC by 32.8% during the 3rd quarter, acquiring 23,906 shares to hold a total of 96,875 shares valued at $9.226 million. Medtronic recently beat quarterly earnings expectations with an EPS of $1.36 and revenue of $8.96 billion, and declared a quarterly dividend of $0.71 per share. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $109.94.

**5. Medtronic stock slips as year-end trading thins and Fed minutes loom**
- Source: ts2.tech | 20251230T043059 | Somewhat-Bearish | Relevance: 100%
- Medtronic shares closed down 0.4% at $96.15 as year-end trading thins, with investors de-risking and awaiting fresh clues on interest rates from upcoming Federal Reserve minutes. The medical-device maker's decline is attributed to macro positioning rather than company-specific news, though its diabetes business, MiniMed, has filed for an IPO. Investors are also looking ahead to Medtronic's fiscal Q3 2026 earnings report on February 17.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $107 | $110 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.7x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.69 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $124.0B |
| Beta | 0.72 |
| 52W Range | $79.38 - $106.33 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.69 |
| Forward P/E | 15.8 |
| Current P/E | 17.1 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.2% to -2.0% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Underperforming sector by 3.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). MACD histogram bearish (-0.53), momentum weakening. RSI neutral at 41. OFD pattern: +STL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.98% (CS: 21) | Neutral |
| RSI_14 | 40.6 | Neutral |
| MACD Histogram | -0.53 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.993x | Below |
| vs SMA200 | 1.059x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $96.67
- **Stop Loss:** $93.87 (2.9% risk)
- **Target:** $99.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 471
- **Position Value:** $45,531.57
- **Portfolio %:** 45.53%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*